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hemorrhage, bronchial- or mainstem stenosis are relatively 
unusual and may develop beyond 4 years after treatment.  
Estimation of the probability to develop RP is important for 
patients with inoperable lung cancer. Studies of the risk of 
RP have used various dosimetric parameters like the Mean 
Lung Dose (MLD) or V20. To increase the sensitivity to predict 
RP, dosimetric and non-dosimetric factors can be combined. 
Palma et al (ref 1) performed a meta-analysis of both 
dosimetric and non-dosimetric factors based on individual 
patients treated with concurrent chemoradiation. The factors 
predicting RP were type of chemotherapy 
(carboplatin/paclitaxel vs cisplatin/etoposide or other 
chemotherapy), age, MLD and V20. Pre-existing radiological 
interstitial lung disease (ILD) findings were analyzed in a 
recent Japanese study of 157 patients and correlated with 
the incidence of RP after stereotactic body radiation therapy 
(SBRT) for stage I NSCLC (ref 2). Multivariate analysis 
identified ILD as risk factor for ≥ Gr2 RP, as well as the 
irradiated lung volume. 
Recall radiation pneumonitis describes a rare reaction in 
previously irradiated lung tissue after application of 
triggering agents. Recall RP has been associated with 
multiple drugs such as taxanes, gemcitabine, vinca alkaloids, 
adriamycin and epirubicin. Tyrosine kinase inhibitors 
(erlotinib, cetuximab, sunitinib) have also been associated 
with recall RP and increased risk of severe RP following 
palliative or definitive radiation therapy. Some researchers 
have found a significant correlation between pulmonary 
toxicity and pre- and post radiation therapy pulmonary 
function tests. However, reduction in e.g. diffusion capacity 
varies widely between the grades of RP, making it less useful 
in routine clinical practice.  
To improve the quality of lung toxicity reporting 
investigations of Patient Reported Outcome (PRO) tools are 
being developed. In literature discrepancies between 
patients and clinicians reported toxicity as well as low 
correlation with CTCAE scoring are reported. Generally 
clinicians tend to underreport the incidence and severity of 
symptoms. In a recently published analysis of lung cancer 
patients treated with radiotherapy/chemoradiation 
agreement ranged from slight to substantial (ref 3). These 
differences underline the significance of the introduction of 
PROs in clinical trials. 
Summary: Dosimetric and clinical factors help us to estimate 
the incidence and severity of radiation induced pulmonary 
toxicity in clinical practice. In addition to these factors PROs 
tools on toxicity should be integrated in daily routine and in 
clinical trials to facilitate the doctors and patients decisions 
in the near future. 
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Radiotherapy (RT) plays a major role in the management of 
lung cancer as most patients are not surgical candidates due 
to stage, fitness and comorbidities. In the last decade we 
have witnessed tremendous changes in the role of radiation 
for the radical treatment of lung cancer as a result of the 
optimisation of chemo-radiotherapy combinations and 
technological advances. 
The technology available for RT planning, delivery and 
verification of lung cancer treatment is evolving at a fast 
pace. Unfortunately the evidence to demonstrate the benefit 
of such technology in terms of toxicity, local control, survival 
or quality of life is limited.  
Despite advances in the field of advanced RT techniques, 
local control with current RT doses delivered with standard 
3D conformal RT is poor with local progression-free survival 
rates of about 30 %, even with concurrent CTRT. It is now 
well accepted that that improved local control in lung cancer 
can lead to improvement in survival [Aupérin A. J Clin Oncol 
2010].   The following strategies can be combined to improve 
outcome in lung cancer include: 
•   Use of  Intensity-modulated radiotherapy 
IMRT is a  technique that adds fluence modulation to beam 
shaping, which improves radiotherapy dose conformity 
around the tumour and spares surrounding normal structures. 
Treatment with IMRT is becoming more widely available for 
the treatment of lung cancer, despite the paucity of high 
level evidence supporting the routine use of this more 
resource intense and complex technique [Chan. JTO 2014]. It 
allows the treatment of patients with large volume disease, 
close to critical organs at risk with curative doses. 
·          Dose escalation 
A clear radiation dose–response relationship exist in locally 
advanced NSCLC [Martel. Lung Cancer 1999]. The relationship 
between local control and BED is further suggested by data 
from SABR studies. The encouraging results of phase 1 and 2 
dose studies conducted in the 1990s formed the basis for the 
RTOG 0617 study [Bradley. ASCO 2013]. In that 2 x 2 factorial 
design study, patients with stage III NSCLC were randomized 
to receive high dose (74 Gy in 37 fractions) or standard dose 
(60 Gy in 30 fractions) RT concurrently with weekly 
paclitaxel/carboplatin with or without cetuximab. 
Disappointingly, there was a significant increase in the risk of 
death in the high-dose arms (median survival, 19.5 months vs 
28.7 months; p=0.0007), and a 37% increase in the risk of 
local failure in the high-dose arms (hazard ratio, 1.37; 
p=0.0319). There is therefore no role for dose escalation in 
stage III NSCLC using conventional dose fractionation 
·          Acceleration  
Hyperfractionated and/or accelerated fractionating 
schedules have demonstrated superior survival compared to 
conventional fractionation at the expense of greater 
oesophageal toxicity [Mauguen JCO 2012] 
·          Dose redistribution based on functional imaging 
Targeted dose escalation to tumour volumes resistant to 
treatment or at increased risk for recurrence is under 
evaluation [NCT01024829 and NCT01507428] 
•           Individualisation  of the dose (concept of isotoxic RT) 
The recognition of cancer heterogeneity has driven us away 
from the ‘one size fits all’ approach and has allowed tailoring 
of treatment to individualised patient-tumour characteristics. 
Isotoxic radiotherapy is a novel concept of personalised 
radiotherapy treatment allowing the individualised 
administration of radiotherapy dose based on predefined 
normal tissue constraints. 
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